Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1
about
CCR5 monoclonal antibodies for HIV-1 therapyHumanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infectionMonoclonal CCR5 antibody for treatment of people with HIV infectionPRO 140 (a CCR5 monoclonal antibody) for treatment in people with HIV infectionNeutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitorsMaraviroc: a review of its use in HIV infection and beyondAccess denied? The status of co-receptor inhibition to counter HIV entryClosing the door to human immunodeficiency virus.Progress towards recombinant anti-infective antibodies.Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.Clinical development of monoclonal antibody-based drugs in HIV and HCV diseasesSynergistic combinations of the CCR5 inhibitor VCH-286 with other classes of HIV-1 inhibitors.Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.The critical need for alternative antiretroviral formulations, and obstacles to their development.Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding siteAntiretroviral drugs: critical issues and recent advancesPotent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugsNew approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonistsMonoclonal antibodies for prophylaxis and therapy of infectious diseases.Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.Maraviroc: a new CCR5 antagonist.Maraviroc in the treatment of HIV infection.Antibody epitopes on g protein-coupled receptors mapped with genetically encoded photoactivatable cross-linkers.Immunotherapeutic restoration in HIV-infected individuals.HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors.Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors.Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults.Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients.Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and preventionUniversal antiretroviral regimens: thinking beyond one-pill-once-a-day.Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitorsHIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry.Combination of the CCL5-derived peptide R4.0 with different HIV-1 blockers reveals wide target compatibility and synergic cobinding to CCR5Parenteral antiretroviral formulations are still urgently needed: a case report and commentary.Dual binding of an antibody and a small molecule increases the stability of TERRA G-quadruplex.Dual Binding of an Antibody and a Small Molecule Increases the Stability of TERRA G-Quadruplex.Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients.
P2860
Q22242739-BB0AE1FF-A5DE-41DE-9A1D-70769A005CADQ24194805-12F5737B-C9B4-4AEA-B37F-0C57ACCF1502Q24235689-2003C511-085D-4BB8-9FF2-9729E2683833Q24239870-4730712B-B116-4D46-8197-14A6AC3AA578Q24655129-809A33AE-A65C-4C61-AC3E-9B0B1FD999EDQ26778504-E072CA95-0C42-4FF4-945B-E8AB78B2FFE1Q28300187-BF6FD0D6-BB5F-4F7F-B09A-5E5C5D213698Q30428089-744BD34A-AD8C-4AE2-AF16-8D3860C41DE1Q33568256-E712A4A5-1099-4744-8F2C-3A46F7112003Q33798442-612AD090-ECDA-469C-B658-416DC40566F7Q34150882-FEE8BFC8-9C27-41D6-8E29-556E1D74673EQ34536782-CCFF3031-C2DD-412D-B14D-02E97A1A464CQ34597465-B39AB8F9-7E5D-46ED-ACE1-F5BA3B6DC9B2Q34757951-1B9728B3-7577-4A58-A8CB-3096F59F3B41Q35164438-40907141-1DD4-4A23-A067-15E267C02288Q35192937-5DA3F9C4-4B9E-4769-9A52-ED55C4F3F063Q36020992-4B10447C-A33E-4D93-B58E-AFB5C18F89EFQ36703042-9CD0C2C6-4F9C-4DEF-B681-5A7BAEF54FACQ36823525-D4F99753-98E1-402A-8D50-CA2230E0AD59Q36989900-3B8B0CD0-DF6F-4868-88D5-A44DE1D2F4BDQ37373656-0E490FC8-DAF3-4B7A-BA8B-11597D4F81A5Q37421895-3CA229F9-1788-4097-8147-426F7A3D301EQ37557671-C7935505-83CC-46B8-958E-960120108843Q37634319-1B3A12F1-5FD1-435B-B874-633C3E38E304Q37701720-9885B621-97D2-45D4-953D-29A36F736ADFQ37842335-AB77F60C-DF67-4D56-8FFF-644AD414DF41Q37855900-3A3075B5-C813-44A4-A54F-2F09209E4536Q38684463-21317BA8-C553-4F72-B10A-4ED39B3B7048Q39098346-024D23DE-3733-4EC8-A701-034DF5670D5AQ39157923-CD29CC1D-CFD5-47DE-9057-D03E6C75A8CEQ39161979-FA3E419A-1816-4A34-AEA4-29B198ED65C2Q39215169-F41FA69F-7303-417D-AB5A-A4B0BC18FDB7Q39433833-94D33D53-2112-496D-ADD5-8EF8C09B89BEQ39454698-0CDDB0DA-06DF-4C8E-8243-6A37B07D04B6Q41895256-448DF083-513A-4F8B-87F6-691AE0AB1FC7Q41897622-95A96CC2-DF7C-48E9-9E42-30EEBB28A444Q42212544-4C465D55-16CF-4C72-A290-5F228CA5BA93Q42354421-736AF18F-B4EA-4E6F-B183-1B98089A865EQ42525813-18D08B4B-5971-4639-9168-4B9FE64F1175Q45948374-76CC1325-C3C6-44A1-AF14-752D956E7A0F
P2860
Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Potent antiviral synergy betwe ...... immunodeficiency virus type 1
@ast
Potent antiviral synergy betwe ...... immunodeficiency virus type 1
@en
Potent antiviral synergy betwe ...... immunodeficiency virus type 1
@nl
type
label
Potent antiviral synergy betwe ...... immunodeficiency virus type 1
@ast
Potent antiviral synergy betwe ...... immunodeficiency virus type 1
@en
Potent antiviral synergy betwe ...... immunodeficiency virus type 1
@nl
prefLabel
Potent antiviral synergy betwe ...... immunodeficiency virus type 1
@ast
Potent antiviral synergy betwe ...... immunodeficiency virus type 1
@en
Potent antiviral synergy betwe ...... immunodeficiency virus type 1
@nl
P2093
P2860
P356
P1476
Potent antiviral synergy betwe ...... immunodeficiency virus type 1
@en
P2093
Daniel C Pevear
Jose D Murga
Michael Franti
Paul J Maddon
William C Olson
P2860
P304
P356
10.1128/AAC.00699-06
P407
P577
2006-10-01T00:00:00Z